Technology
The Chapel Hill Project serves as a depository for intellectual property that can be used for the development of cell and gene therapies for orphan diseases. The Project is being granted access to Asklepios BioPharmaceutical, Inc.'s platform technology and hopes that other companies will contribute use of their DNA-based technologies to speed the advancement of orphan disease therapeutics to the market. In addition, the Project will be advised by a board of key clinicians and scientists acting as guides for researchers by helping them turn scientific research into cost-effective, viable treatment options.
The Project will provide researchers, with no upfront costs, with access to technologies deposited with the foundation over time, scientific data and expertise, clinical development assistance, cross-references to regulatory filings and grant writing and other funding assistance.
Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc. ("AskBio") (www.askbio.com) will provide the Chapel Hill Project with access to its proprietary Biological NanoParticle (BNPTM) and Self-Complementary Vector technologies, which were developed at the University of North Carolina at Chapel Hill and exclusively licensed to AskBio, for the treatment of certain orphan diseases. The Chapel Hill Project will make this technology available to researchers for the use in developing novel treatments for orphan disease indications.
